Ascentage Pharma Group International issued an announcement on July 13, 2026, regarding further grants of awards under its 2021 Restricted Share Unit (RSU) Scheme, 2022 RSU Scheme, and the Post IPO Share Option Scheme. The company is a biopharmaceutical firm focused on developing innovative medicines.
